Hydrogen's Feasibility and Safety as a Therapy in ECPR

Summary

The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.

Timeline

Start

2024-03-04

Primary completion

2027-03-31

Completion

2027-08-31

Publications

• Habet V, DeWaard T, Boggs KM, Fetch A, Puente BN, Sleeper LA, Kheir JN. Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest. Trials. 2025 Nov 7;26(1):481. doi: 10.1186/s13063-025-09217-7.

Drugs

Indications